Results of Calando's targeted nanoparticles in preclinical cancer study

October 01, 2007 | Analyst Insight

Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research (NASDAQ: ARWR), announced last week that a preclinical study of its nucleic acid nanoparticle delivery technology to target tumors in mice was...